Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,048 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress

NCT05213000
View directory record Official record
Conditions
Immunization
Interventions
Exercise
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of IFN-γ on Innate Immune Cells

NCT02609932
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Administration of drug (Interferon-gamma 1-b) subcutaneously
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wheat Bioactives and Immune Function

NCT02210234
View directory record Official record
Conditions
Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions
50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1Phase 2 Interventional

Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?

NCT01195077
View directory record Official record
Conditions
HIV Infections
Interventions
seaweed, spirulina, seaweed + spirulina
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 24, 2026, 8:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Results available

Cancer Vaccine Targeting Brachyury Protein in Tumors

NCT01519817
View directory record Official record
Conditions
Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
Interventions
GI-6301 (Yeast Brachyury Vaccine)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 24, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional

Walnuts as an Infant Solid Food for Health

NCT07081698
View directory record Official record
Conditions
Gut -Microbiota, Inflammatory Markers, Infant Development
Interventions
Infant walnut intake
Other
Lead sponsor
Colorado State University
Other
Eligibility
5 Months to 5 Months
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

NCT00007332
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

NCT00091702
View directory record Official record
Conditions
HIV Infections, Influenza
Interventions
Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Immune Responses to Influenza Vaccination

NCT03346772
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Influenza vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 8:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

PET-CT Scans in Healthy Volunteers After Flu Vaccination

NCT00769002
View directory record Official record
Conditions
Flu
Interventions
FluShield, FluShield - same arm, FluShield - opposite arm, Blood Draws, FDG PET-CT Scan, Cytokine Profiling
Biological · Procedure · Genetic
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 24, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
ImmunoPulse, Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid
Device · Drug · Biological
Lead sponsor
Chase Heaton, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 24, 2026, 8:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 24, 2026, 8:57 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses

NCT00001257
View directory record Official record
Conditions
Healthy Volunteers, Abnormal Phagocyte Function
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

NCT01733056
View directory record Official record
Conditions
Immunosuppression
Interventions
Flu Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Results available

Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)

NCT03661541
View directory record Official record
Conditions
HSV, Herpes Labialis
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

NCT01911065
View directory record Official record
Conditions
Herpes Zoster
Interventions
Zostavax™
Biological
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 24, 2026, 8:57 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

NCT05432583
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
BNT163, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Vitamin D in Female Reproductive Tract Immunity

NCT02186535
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D and Calcium
Dietary Supplement
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 24, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

NCT00959049
View directory record Official record
Conditions
Influenza
Interventions
CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 17 Years
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
23
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 24, 2026, 8:57 PM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 24, 2026, 8:57 PM EDT